Seelos Therapeutics closes enrollment in study of SLS-002

Seelos Therapeutics announced the close of enrollment of its registration directed study of SLS-002 for Acute Suicidal Ideation and Behavior in adults with Major Depressive Disorder. “The close of enrollment of our ASIB study is a major milestone for Seelos and the credit goes to our hard-working clinical team enrolling subjects in this very challenging and difficult-to-treat population. Suicides have devastating effects on families and communities but sadly there is no effective therapy available as of today,” said Raj Mehra Ph.D., Chairman and CEO of Seelos. “We look forward to completing the study and sharing the results in the third quarter of 2023.”